Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib versus docetaxel in previously treated stage IV squamous non-small cell lung cancer
2014-004832-20Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Pulmonary squamous cell carcinoma comparing Abemaciclib with Docetaxel (2 arms). Primary endpoint: Progression-free survival. Started May 2015; status: completed.
02
Drugs
abemaciclibdocetaxel
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2014-004832-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004832-20.